Terns Pharmaceuticals (TERN) Stock Statistics & Valuation Metrics

Terns Pharmaceuticals has a market cap or net worth of $4.05B. The enterprise value is $394.07M.

Terns Pharmaceuticals has 90,079,780 shares outstanding. The number of shares has decreased by -2.65% in one year.

Terns Pharmaceuticals’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -29.30%.

The current PE Ratio of Terns Pharmaceuticals is ―. Terns Pharmaceuticals’s PEG ratio is 0.42.

In the last 12 months, Terns Pharmaceuticals had revenue of 0.00 and earned -88.85M in profits. Earnings per share was -1.12.

In the last 12 months, operating cash flow was -77.68M and capital expenditures 0.00, giving a free cash flow of -77.68M billion.

Terns Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Terns Pharmaceuticals upcoming earnings date is Mar 31, 2026, After Close (Confirmed).

Terns Pharmaceuticals as a current ratio of 23.14, with Debt / Equity ratio of 0.37%

In the past 12 months, Terns Pharmaceuticals has paid 260.00K in taxes.

Terns Pharmaceuticals EV to EBITDA ratio is -3.20, with an EV/FCF ratio of -4.00.

Terns Pharmaceuticals has $295.63M in cash and marketable securities with $1.03M in debt, giving a net cash position of $294.61M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Terns Pharmaceuticals is $46.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy